News | Mammography | June 30, 2017

Solis Mammography Ranks No. 19 in Dallas Business Journal’s Middle Market 50

Nation’s largest independent provider of breast screening services recognized for improving technology, leading to fewer recalls and higher retention rates

Solis Mammography Ranks No. 19 in Dallas Business Journal’s Middle Market 50

June 30, 2017 — Solis Mammography was named the 19th fastest-growing, middle-market company in North Texas by the Dallas Business Journal. Rankings of the publication’s third annual research project were based on both private and public companies with revenue between $25 million and $750 million. Fifty-three companies that met the annual revenue requirements in the 2017 Middle Market 50 were awarded at the 2017 Middle Market 50 Awards Dinner at the Ritz Carlton in Dallas.

Headquartered in Addison, Texas, Solis currently operates 37 centers across six major markets – North Texas; Houston, Texas; Phoenix, Ariz.; Columbus, Ohio; Greensboro, N.C.; and, through its acquisition of Washington Radiology, the D.C. metropolitan area. The company operates both wholly-owned centers and multiple joint ventures with hospital partners. Solis Mammography (including Washington Radiology) serves more than 600,000 patients each year with highly-specialized breast imaging services including screening and diagnostic mammography (2-D and 3-D), computer-aided detection, breast ultrasound, stereotactic biopsy and ultrasound-guided biopsy.

Over the past three years, the company has committed $16 million to upgrade all of its centers with 3-D mammography (also known as digital breast tomosynthesis), lowering unnecessary recalls by 37 percent and increasing cancer detection by 54 percent. Taken together, these changes have earned the company a 76 percent annual retention rate with returning patients, far higher than the national average of 53 percent.

Under the leadership of James Polfreman, the company has more than doubled its footprint since he joined the company in 2011, increasing revenue by more than 250 percent and creating a fivefold increase in bottom line, earnings before interest, tax, depreciation and amortization (EBITDA).

For more information: www.solismammo.com

Related Content

Eizo RadiForce RX560 Monitor Receives FDA 510(k) for Tomosynthesis and Digital Mammography
Technology | November 20, 2017
Eizo Corp. announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for breast tomosynthesis...
Biop Medical Launches Cervical Cancer Diagnosis Technology at MEDICA 2017

Biop Medical cervical cancer detection system

Technology | Women's Health | November 13, 2017
November 13, 2017 — Biop Medical announced it will present its point-of-care...
Kansas City Radiology Center Employs iCAD PowerLook Tomo Detection for DBT
News | Computer-Aided Detection Software | November 10, 2017
November 10, 2017 — Imaging for Women, a leading radiology center in Kansas City, Mo., announced it is now using iCAD
Kubtec Brings Image Analytics Capabilities to Tomosynthesis Specimen Imaging Systems
News | Mammography | November 10, 2017
Kubtec announced it will be showcasing new image analytics capabilities on its advanced tomosynthesis specimen imaging...
Siemens Healthineers Introduces Share360 Tailored Service Portfolio
News | Imaging | November 10, 2017
November 10, 2017 — To address the specific needs of...
Fujifilm Highlights Women's Health and Pediatrics at RSNA 2017
News | Information Technology | November 08, 2017
November 8, 2017 — Fujifilm Healthcare will showcase a variety of imaging and information technology solutions at the
CureMetrix Expands Medical Advisory Board
News | Computer-Aided Detection Software | November 08, 2017
November 8, 2017 — CureMetrix, a company developing...
ICPME Makes EQUIP Mammography Inspection CME/CE Webinar Available Online
News | Mammography | November 08, 2017
November 8, 2017 — In conjunction with Brea...
Study Suggests Breast Cancer Patients Forego Post-Surgery Treatment Due to Mistrust
News | Radiation Therapy | November 06, 2017
November 6, 2017 — Nearly one-third of women with...
Study shows tissue marker reduces radiation target volumes, produces many other advantages

These CT images show placement of a 3-D fixed array implanted fiducial (3-D marker) at the time of oncoplastic tumor resection. The original LCTV (LCTVo) was retrospectively re-contoured by the radiation oncologist (LCTVro) and breast surgeon (LCTVbs). Thereafter, both re-contours were combined to create the collaborative LCTV (LCTVc), which required agreement of both the radiation oncologist and breast surgeon. Volume differences between the original LCTV (LCTVo) and the collaborative LCTVc were then evaluated, and demonstrated a mean and median reduction in LCTV.

Feature | Tumor Tracking Systems | November 06, 2017 | By William Hall, M.D.
Radiation planning for breast cancer relies on accurate delineation of the post-lumpectomy target volume as identified...
Overlay Init